企業プロフィール
SeaStar Medical 株価・ニュース・カタリスト
- ティッカー:
- ICU
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
3.25 USD (+2.20%)
終値
最終更新: 2026年8月17日
14.1M USD
時価総額
株価変動の要因
As of Aug 17, 2026, ICU closed up 2.20% at $3.25. No new same-company headline was identified in the current news window.
企業概要
Organ-Failure Immunomodulation Company
SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation.
Selective Cytopheretic Device
The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of inflammatory immune cells.
QUELIMMUNE
QUELIMMUNE is authorized for pediatric acute kidney injury and is being adopted by children’s hospitals under a Humanitarian Device Exemption.
Adult AKI Program
The pivotal NEUTRALIZE-AKI trial is evaluating the SCD in adults with acute kidney injury requiring continuous renal replacement therapy.
今後のカタリスト
- Completion of enrollment in the pivotal NEUTRALIZE-AKI trial is targeted around year-end 2026.
- SeaStar plans to begin submitting PMA modules to the FDA as the adult AKI program progresses, with a potential full PMA filing in 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。